Literature DB >> 25217083

Intratympanic steroids as a salvage treatment for sudden sensorineural hearing loss? A meta-analysis.

Jia Hui Ng1, Roger Chun Man Ho, Crystal Shuk Jin Cheong, Adele Ng, Heng Wai Yuen, Raymond Yeow Seng Ngo.   

Abstract

Sudden sensorineural hearing loss is typically treated with systemic steroids. The aim of this meta-analysis was to evaluate the efficacy of salvage intratympanic steroid treatment in patients who have initial treatment failure with systemic steroids. A MEDLINE literature search was performed, supported by searches of Web of Science, Biosis, and Science Direct. Articles of all languages were included. Selection of relevant publications was conducted independently by three authors. Only randomized controlled trials were considered. In one arm of the studies, the patients received salvage intratympanic steroids. In the other arm, patients did not receive further treatment. The standard difference in mean (SDM) amount of improvement in hearing threshold between patients who did and did not receive salvage intratympanic steroids was calculated. From an initial 184 studies found via the search strategy, 5 studies met inclusion criteria and were included. There was a statistically significant greater reduction in hearing threshold on pure-tone audiometry in patients who received salvage intratympanic steroids than in those who did not (SDM = -0.401, p = 0.005). Subgroup analysis showed that administration by intratympanic injection (SDM = -0.375, p = 0.013) rather than a round window catheter (SDM = -0.629, p = 0.160) yielded significant improvement in outcome. The usage of dexamethasone yielded better outcomes (SDM = -0.379, p = 0.039) than the use of methylprednisolone (SDM = -0.459, p = 0.187). No serious side effect of treatment was reported. In patients who have failed initial treatment with systemic steroids, additional treatment with salvage intratympanic dexamethasone injections demonstrate a statistically significant reduction in the hearing thresholds as compared to controls.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25217083     DOI: 10.1007/s00405-014-3288-8

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  42 in total

1.  Vasoactive therapy versus placebo in the treatment of sudden hearing loss: a double-blind clinical study.

Authors:  J Kronenberg; M Almagor; E Bendet; D Kushnir
Journal:  Laryngoscope       Date:  1992-01       Impact factor: 3.325

2.  Intratympanic dexamethasone/hyaluronic acid mix as an adjunct to intravenous steroid and vasoactive treatment in patients with severe idiopathic sudden sensorineural hearing loss.

Authors:  Haralampos Gouveris; Wiebke Schuler-Schmidt; Torsten Mewes; Wolf Mann
Journal:  Otol Neurotol       Date:  2011-07       Impact factor: 2.311

3.  Steroids, carbogen or placebo for sudden hearing loss: a prospective double-blind study.

Authors:  U Cinamon; E Bendet; J Kronenberg
Journal:  Eur Arch Otorhinolaryngol       Date:  2001-11       Impact factor: 2.503

4.  Treatment of sudden sensorineural hearing loss: II. A Meta-analysis.

Authors:  Anne Elizabeth Conlin; Lorne S Parnes
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-06

5.  Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL.

Authors:  Seok Min Hong; Chan Hum Park; Jun Ho Lee
Journal:  Otolaryngol Head Neck Surg       Date:  2009-11       Impact factor: 3.497

6.  Clinical efficacy of initial intratympanic steroid treatment on sudden sensorineural hearing loss with diabetes.

Authors:  Chi-Sung Han; Jong-Ryul Park; Sung-Hyun Boo; Joon-Man Jo; Kyung-Won Park; Won-Yong Lee; Joong-Gi Ahn; Myung-Koo Kang; Byung-Gun Park; Hyun Lee
Journal:  Otolaryngol Head Neck Surg       Date:  2009-10-01       Impact factor: 3.497

7.  Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment.

Authors:  Ho Guan-Min Ho; Hung-Ching Lin; Min-Tsan Shu; Cheng-Chien Yang; Hsun-Tien Tsai
Journal:  Laryngoscope       Date:  2004-07       Impact factor: 3.325

8.  Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss.

Authors:  Alex Battaglia; Raoul Burchette; Roberto Cueva
Journal:  Otol Neurotol       Date:  2008-06       Impact factor: 2.311

9.  Calcium antagonists in the treatment of sudden deafness.

Authors:  W Mann; C Beck; C Beck
Journal:  Arch Otorhinolaryngol       Date:  1986

10.  Should hyperbaric oxygen be added to treatment in idiopathic sudden sensorineural hearing loss?

Authors:  Ebru Topuz; Ozgur Yigit; Ugur Cinar; Huseyin Seven
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-10-29       Impact factor: 2.503

View more
  18 in total

1.  Systemic, intratympanic and combined administration of steroids for sudden hearing loss. A prospective randomized multicenter trial.

Authors:  Michael Tsounis; George Psillas; Miltiadis Tsalighopoulos; Victor Vital; Nicolas Maroudias; Konstantinos Markou
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-11-22       Impact factor: 2.503

Review 2.  Intratympanic corticosteroids for sudden sensorineural hearing loss.

Authors:  Stefan K Plontke; Christoph Meisner; Sumit Agrawal; Per Cayé-Thomasen; Kevin Galbraith; Anthony A Mikulec; Lorne Parnes; Yaamini Premakumar; Julia Reiber; Anne Gm Schilder; Arne Liebau
Journal:  Cochrane Database Syst Rev       Date:  2022-07-22

3.  Efficacy and safety of systemic, high-dose glucocorticoid therapy for idiopathic sudden sensorineural hearing loss : Study protocol for a three-armed, randomized, triple-blind, multicenter trial (HODOKORT).

Authors:  Stefan K Plontke; Matthias Girndt; Christoph Meisner; Iris Böselt; Beatrice Ludwig-Kraus; Michael Richter; Torsten Rahne
Journal:  HNO       Date:  2022-06-20       Impact factor: 1.330

4.  Prognostic factors for profound sudden idiopathic sensorineural hearing loss: a multicenter retrospective study.

Authors:  Ho Yun Lee; Dong-Kee Kim; Yong-Ho Park; Wang Woon Cha; Geun Jeon Kim; Seung Hun Lee
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-20       Impact factor: 2.503

5.  Intratympanic steroid use for idiopathic sudden sensorineural hearing loss: current otolaryngology practice in Germany and Austria.

Authors:  L Sutton; V Schartinger; C Url; J Schmutzhard; D Lechner; C Kavasogullari; J S Sandhu; A Shaida; R Laszig; J Loehler; S Plontke; H Riechelmann; M Lechner
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-03-31       Impact factor: 2.503

6.  Hearing Changes After Intratympanic Steroids for Secondary (Salvage) Therapy of Sudden Hearing Loss: A Meta-Analysis Using Mathematical Simulations of Drug Delivery Protocols.

Authors:  Arne Liebau; Olivia Pogorzelski; Alec N Salt; Stefan K Plontke
Journal:  Otol Neurotol       Date:  2018-08       Impact factor: 2.311

7.  Nanoparticle mediated drug delivery of rolipram to tyrosine kinase B positive cells in the inner ear with targeting peptides and agonistic antibodies.

Authors:  Rudolf Glueckert; Christian O Pritz; Soumen Roy; Jozsef Dudas; Anneliese Schrott-Fischer
Journal:  Front Aging Neurosci       Date:  2015-05-19       Impact factor: 5.750

8.  Acquired sensorineural hearing loss in children: current research and therapeutic perspectives.

Authors:  M Ralli; R Rolesi; R Anzivino; R Turchetta; A R Fetoni
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-12       Impact factor: 2.124

9.  Clinical Analysis of Intratympanic Injection of Dexamethasone for Treating Sudden Deafness.

Authors:  Xin Li; Wen-Jing Chen; Jia Xu; Hai-Jin Yi; Jing-Ying Ye
Journal:  Int J Gen Med       Date:  2021-06-16

10.  [Hormonal influence on hearing].

Authors:  J M Vahl; E Goldberg-Bockhorn; T K Hoffmann; M C Wigand
Journal:  HNO       Date:  2021-03-16       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.